Chardan Reiterates Buy Rating on Orchestra BioMed Inc. (OBIO): "warrants a new look by investors" Mar 12, 2026 03:17PM
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences Apr 28, 2025 04:30PM
Today's most important initiations Feb 7, 2023 05:53PM
Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model Jan 27, 2023 08:00AM